-
1.发明授权公开(公告)号：US11826724B2
公开(公告)日：2023-11-28
申请号：US17372985
申请日：2021-07-12
Applicant: CytoSorbents Corporation
Inventor： Tamaz Guliashvili , Thomas Golobish , Maryann Gruda , Pamela O'Sullivan , Andrew Scheirer , Vincent Capponi , Phillip Chan , Wei-Tai Young
IPC: A61K38/00 , B01J20/26 , B01D15/34 , B01J20/28 , B01J20/32 , A61K9/00 , A61K31/745 , A61M1/36 , B01D15/12
CPC classification number: B01J20/261 , A61K9/0031 , A61K9/0053 , A61K31/745 , A61M1/3679 , B01D15/34 , B01J20/262 , B01J20/267 , B01J20/2808 , B01J20/28069 , B01J20/28078 , B01J20/28083 , B01J20/28085 , B01J20/327 , B01J20/3208 , B01J20/3231 , B01J20/3272 , B01J20/3274 , B01J20/3289 , B01D15/125
Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.
-
公开(公告)号：US09931357B2
公开(公告)日：2018-04-03
申请号：US15515328
申请日：2015-10-02
Applicant: CYTOSORBENTS CORPORATION
Inventor： Humayra Begum Ali , Thomas D. Golobish , Vincent J. Capponi , Phillip P. Chan , Wei-Tai Young , Andrew Robert Scheirer
IPC: A61M31/00 , A61K31/74 , A61K31/765 , A61K9/00
CPC classification number: A61K31/765 , A61K9/0053 , A61K31/75 , A61K31/79 , A61P1/00 , A61P1/04 , A61P1/06
Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
-
公开(公告)号：US11040061B2
公开(公告)日：2021-06-22
申请号：US15769361
申请日：2016-10-21
Applicant: CYTOSORBENTS CORPORATION
Inventor： Thomas Golobish , Maryann Gruda , Tamaz Guliashvili , Pamela O'Sullivan , Andrew Scheirer , Vi Dan , Wei-Tai Young , Vincent Capponi , Phillip Chan
IPC: A61K31/795 , A61K47/20 , A61K47/26 , A61M5/165 , B01J20/26 , B01J39/20 , B01J20/28 , A61M1/36 , A61M5/14
Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising a sulfonic acid salt functionality designed to adsorb a broad range of protein based toxins from less than 0.5 kDa to 1,000 kDa and positively charged ions including but not limited to potassium.
-
公开(公告)号：US10946040B2
公开(公告)日：2021-03-16
申请号：US16424747
申请日：2019-05-29
Applicant: Cytosorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K31/74 , A61K31/75 , A61K9/00 , A61K9/16 , A61K9/50 , B01J20/26 , B01J20/28 , B01J20/30 , C08F212/36 , C08J9/26 , A61K47/58
Abstract: The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.
-
公开(公告)号：US11969535B2
公开(公告)日：2024-04-30
申请号：US16645965
申请日：2018-09-13
Applicant: CYTOSORBENTS CORPORATION
Inventor： Dominik Gutzler , Wei-Tai Young
CPC classification number: A61M1/3666 , A61M1/1698 , A61M1/3679 , A61M39/24 , A61M39/28 , A61M1/3623 , A61M2202/0415
Abstract: Connector assemblies and methods of replacing components in an extra-corporeal circuit (ECC) system are disclosed. A connector assembly for use in an ECC system includes a tubular body having an inner surface defining a lumen extending through the tubular body with the lumen extending along a longitudinal axis, a first connection interface in fluid communication with the lumen, a second connection interface in fluid communication with the lumen, and a plurality of closure mechanisms, each closure mechanism being configured to occlude the lumen.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240082817A1
公开(公告)日：2024-03-14
申请号：US18502809
申请日：2023-11-06
Applicant: CytoSorbents Corporation
Inventor： Tamaz Guliashvili , Thomas Golobish , Maryann Gruda , Pamela O'Sullivan , Andrew Scheirer , Vincent Capponi , Phillip Chan , Wei-Tai Young
CPC classification number: B01J20/261 , A61K9/0031 , A61K9/0053 , A61K31/745 , A61M1/3679 , B01D15/34 , B01J20/262 , B01J20/267 , B01J20/28069 , B01J20/28078 , B01J20/2808 , B01J20/28083 , B01J20/28085 , B01J20/3208 , B01J20/3231 , B01J20/327 , B01J20/3272 , B01J20/3274 , B01J20/3289 , B01D15/125
Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules.
-
7.发明申请公开(公告)号：US20220032267A1
公开(公告)日：2022-02-03
申请号：US17372985
申请日：2021-07-12
Applicant: CytoSorbents Corporation
Inventor： Tamaz Guliashvili , Thomas Golobish , Maryann Gruda , Pamela O'Sullivan , Andrew Scheirer , Vincent Capponi , Phillip Chan , Wei-Tai Young
Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.
-
公开(公告)号：US11058715B2
公开(公告)日：2021-07-13
申请号：US15172209
申请日：2016-06-03
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Humayra Begum Ali
IPC: A61K31/745 , A61K31/74 , A61K31/75 , A61K9/00 , A61K9/16 , A61K9/50 , B01J20/26 , B01J20/28 , B01J20/30 , C08F212/36 , C08J9/26 , A61K47/58
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
-
公开(公告)号：US20160279163A1
公开(公告)日：2016-09-29
申请号：US15172209
申请日：2016-06-03
Applicant: CytoSorbents Corporation
Inventor： Phillip P. Chan , Wei-Tai Young , Vincent J. Capponi , Thomas D. Golobish , Robert H. Bartlett , Humayra Begum Ali
IPC: A61K31/745 , A61K9/00 , A61K47/48
CPC classification number: A61K31/745 , A61K9/0053 , A61K9/16 , A61K9/50 , A61K31/74 , A61K31/75 , A61K47/58 , B01J20/261 , B01J20/28004 , B01J20/28073 , B01J20/28076 , B01J20/3064 , C08F212/36 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2325/02 , Y02A50/406 , Y02A50/411
Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
Abstract translation: 本发明涉及从患有或处于炎症风险的患者处理全身，局部或局部炎症的方法，其包括施用治疗有效剂量的吸附所述患者中的炎性介质的吸附剂。 在一些优选实施方案中，吸附剂是生物相容性有机聚合物。
-
公开(公告)号：US20230310693A1
公开(公告)日：2023-10-05
申请号：US18022018
申请日：2021-08-19
Applicant: CYTOSORBENTS CORPORATION
Inventor： Phillip P. CHAN , Ophir ORTIZ , Thomas D. Golobish , Vincent J. CAPPONI , Wei-Tai Young
CPC classification number: A61L15/44 , A61L15/425 , A61L15/38 , A61L2300/254 , A61L2300/43 , A61L2300/402 , A61L2300/414
Abstract: The invention concerns methods for the selective, topical or trans dermal delivery or removal of one or more substances to, or from, respectively, the skin or surface of a human or animal subject, via the topical or transdermal application of a porous, polymeric composition capable of releasing or sorbing (adsorbing and/or absorbing) said substances, wherein said porous polymer is a particulate material, with particles having an average diameter in the range of approximately 0.1 microns to approximately 0.5 centimeters, and having a plurality of pores with an average pore diameter in a range of approximately 50 Angstroms to approximately 40,000 Angstroms.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.016 seconds)
